随机对照试验
医学
康复
心理干预
医疗保健
生活质量(医疗保健)
整群随机对照试验
精神分裂症(面向对象编程)
照顾负担
干预(咨询)
物理疗法
质量调整寿命年
星团(航天器)
间接成本
治疗组和对照组
门诊护理
住院治疗
梅德林
成本效益
经济评价
心理健康
卫生经济学
患者满意度
社区康复
急诊医学
医疗急救
作者
Ruoxi Ding,M. H. Zhao,Yiqi Xia,Yanshang Wang,Zhenyu Shi,Xiaohong Hu,Li Ling,Ping He
标识
DOI:10.1093/schbul/sbag014
摘要
BACKGROUND: Schizophrenia is a leading global disability, with severe treatment gaps in low-resource settings. Community-based rehabilitation (CBR) is promising but lacks robust evidence on its impacts on healthcare utilization. STUDY METHODS: We conducted a cluster-randomized controlled trial across 18 urban and rural subdistricts in Weifang City, Shandong province, China, enrolling 334 participants with schizophrenia. Communities were randomly assigned to receive either facility-based care (FBC) enhanced with CBR (n = 172) or standard FBC alone (n = 162). The main outcomes of this study included outpatient/inpatient utilization, costs, and self-treatment over 6- and 12-month follow-up periods, collected through medical insurance claims and structured questionnaires. We systematically monitored intervention quality using the validated Comprehensive Psychotherapeutic Interventions Rating Scale. STUDY RESULTS: At 6 months, CBR participants had significantly lower outpatient costs vs. controls (total: -CNY748.6 [82.4% reduction], 95%CI, -1124.3 to -373.0; schizophrenia-specific: -CNY529.0 [79.1% reduction], -833.5 to -224.4) and reduced out-of-pocket (OOP) costs (total: -CNY216.9; schizophrenia-related: -CNY113.2). By 12 months, inpatient cost reductions emerged (total: -CNY1710.4 [78.2% reduction]; OOP: -CNY405.8 [78.1% reduction]) despite similar admission rates. Self-treatment increased (0.77 more episodes) with no cost differences. Higher quality predicted greater outpatient visit reductions at 12 months (β = -0.10) and inpatient visit reductions at 6 months (β = -0.21), with group dynamics and directive behaviors most beneficial. CONCLUSION: CBR significantly reduces healthcare costs and improves self-management. Quality-driven effects on utilization support scaled implementation in resource-limited settings, particularly via group-based approaches. Integrating high-quality CBR is critical to curb the rising economic burden in low-resource countries. TRIAL REGISTRATION: ClinicalTrials.gov identifier: ChiCTR2200066945.
科研通智能强力驱动
Strongly Powered by AbleSci AI